RFK Jr. opens new chapter in US vaccine policy
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has opened a new chapter of federal vaccine policy that invites questions on issues long considered to be settled and that pushes anti-vaccine priorities into mainstream government guidelines.
During his Senate confirmation hearings, Kennedy said he wouldn't undermine vaccines.
'I am not going to go into HHS and impose my preordained opinions on anybody at HHS,' he said. 'I'm going to empower the scientists at HHS to do their job and make sure that we have good science that is evidence based.'
Over the course of a two-day meeting this week, Kennedy's handpicked panel of vaccine advisers said they would launch an investigation into the cumulative effect of the childhood and adolescent vaccine schedules and consider new recommendations for shots that have long been on the market.
'Vaccines are not all good or bad,' said Martin Kulldorff, the committee's new chair and a former Harvard University professor. 'No questions should be off-limits.'
The panel also voted to effectively remove an ingredient from flu shots that has long been the target of anti-vaccine activists, including Kennedy, despite numerous studies showing it is safe.
The vote was not unanimous with two of the seven members abstaining or voting 'no' on the question of only recommending thimerosal-free flu vaccines.
'I think this is a prelude to them demonstrating their ability to go in with this committee, make recommendations to pull some of these vaccines,' former FDA Commissioner Scott Gottlieb said during a recent CNBC interview.
Gottlieb noted the backlash to pandemic-era measures like vaccine mandates launched a backlash Kennedy is taking advantage of.
'We've now built a lot of anti-vaccine sentiment. Secretary Kennedy is fueling that with what he's doing in groups like the ACIP that he's constituted. The consequences of this are going to be felt for years,' Gottlieb said.
In early June, Kennedy fired the Centers for Disease Control and Prevention's (CDC) entire Advisory Committee on Immunization Practices (ACIP) and installed eight new members, several of whom have openly questioned vaccines.
The panel met with just seven members after one person dropped out prior to the meeting.
On Thursday, the ACIP voted to no longer recommend any flu vaccines containing the preservative thimerosal, based on the presentation of a single vaccine critic.
Lyn Redwood, a nurse practitioner and a former leader of Kennedy's anti-vaccine group, said thimerosal is a 'developmental and reproductive toxicant' that never underwent proper safety testing.
The CDC removed a copy of her initial presentation from its website earlier this week after it appeared to cite a nonexistent study.
Redwood was recently hired by HHS and is listed as an 'expert' in the agency's employee directory. She presented her argument against thimerosal as a private citizen, however, not as a representative of the federal government.
Thimerosal is a rarely used ingredient, so the real-world impact of the vote is likely minimal. It's used in multi-dose vials in order to prevent the growth of bacteria and fungi and is more commonly used in low-income countries.
But the vote showed the panel's willingness to disregard scientific data and empower people with longstanding grievances against the public health establishment and the anti-vaccine movement to make policy recommendations for the entire country.
'What we heard in this meeting was really a false narrative that the current vaccine policies are flawed and that they need fixing,' said Sean O'Leary, chair of the American Academy of Pediatrics Committee on Infectious Diseases, in a press conference. 'That's completely false. These policies have saved millions of lives, trillions of dollars.'
AAP said it will no longer take part in the proceedings because they are not 'credible.'
Public health experts said Redwood's presentation at the meeting went against the standards of what a group like the ACIP should uphold.
Jerome Adams, who served as surgeon general in the first Trump administration, said in a post on the social platform X that the presentation 'bypassed normal CDC vetting, cherry-picked outdated data, and ignored decades of safety evidence.'
Elizabeth Jacobs, professor emerita from the department of epidemiology at the University of Arizona and co-founder of the Defend Public Health advocacy network, described the meeting as a 'circus-like atmosphere' rather than the typically staid, academic one.
'Lynn Redwood was permitted to give a presentation that was just simply deceptive about thimerosal and vaccines. And that type of behavior is really not something that a serious scientific body should be considering,' Jacobs told The Hill. 'It is entirely inappropriate to have a person present at a scientific meeting one side of an issue with very weak evidence and completely ignore the decades of data showing the safety and effectiveness of thimerosal.'
One ACIP member, the sole member to vote 'No' on recommending only thimerosal-free flu shots, expressed concerns that the vote could lead to reduced vaccine access abroad as other countries look to the panel for guidance.
'The recommendations that the ACIP makes are followed among many countries around the world and removing thimerosal from all vaccines that are used in other countries, for example, is going to reduce access to these vaccines,' said Cody Meissner, professor of pediatrics at the Geisel School of Medicine at Dartmouth College who previously served on the ACIP.
'It will increase cost. And I think it's important to note that no study has ever indicated any harm from thimerosal. It's been used in vaccines, as was noted by Ms. Redwood, since before World War II,' he added.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
33 minutes ago
- Medscape
Which Immunoglobulin Route Best Prevents Infections?
TOPLINE: In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection rates than the intravenous and facilitated subcutaneous routes. METHODOLOGY: Researchers conducted a cross-sectional study to compare the incidence of viral infections among immunocompromised patients who had been receiving IRT via different administration routes for more than 5 years. They included 58 patients (56.8% boys; median age, 17 years; median age at diagnosis, 11.5 years) with inborn errors of immunity. The intravenous route was the most common route of immunoglobulin administration (n = 32), followed by the conventional subcutaneous (n = 16) and facilitated subcutaneous (n = 10) routes. Patients underwent monitoring of immunoglobulin levels and had nasal swab collected monthly, with viral infections recorded when symptoms such as runny nose, cough, or fever were present. Infections from different immunoglobulin administration routes were analyzed by polymerase chain reaction testing of nasal swabs and serum immunoglobulin levels using nephelometry. TAKEAWAY: The overall viral infection frequency was 3.79%, with rates of 4.2% for the intravenous route, 2.5% for the conventional subcutaneous route, and 4.4% for the facilitated subcutaneous route of immunoglobulin administration. The conventional subcutaneous route associated with significantly lower infection rates than the other routes (P < .05). Adenovirus (21.8%), influenza A virus (16.4%), and human rhinovirus/enterovirus (16.4%) were the most frequently detected viral agents. At 3 months, patients with X-linked agammaglobulinemia (6.06%) and those with common variable immunodeficiency (3.65%) had the highest rates of viral infections. IN PRACTICE: 'Shared decision-making between patients and healthcare professionals is critical in determining the most appropriate administration route and product to minimize the risk of infections and achieve optimal treatment outcomes,' the authors wrote. SOURCE: The study was led by Hulya Kose, Department of Pediatric Immunology and Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey. It was published online on May 30, 2025, in the European Journal of Pediatrics. LIMITATIONS: This research had limitations due to the small sample size within specific patient subgroups. DISCLOSURES: The study did not receive any specific funding. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Associated Press
44 minutes ago
- Associated Press
U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc. (OTC: GLUC) Patent Pending Soluble Fiber-Based Nutrition Formulation
BENTONVILLE, Ark., June 30, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA) official recognition and designation of dietary fiber as a nutrient of public health concern in the Dietary Guidelines for Americans, 2020–20251. Dietary fiber is one of four nutrients identified by HHS and USDA as critically under-consumed, to the detriment of the well-being of Americans. This federal designation of public health concern underscores a significant public health deficiency and is expected to drive increased government funding of dietary fiber awareness campaigns leading to follow-on demand for dietary fiber-based nutrition solutions. Among the companies best positioned to benefit from the designation issued by HHS and USDA is Glucose Health, Inc., which began scientific formulation and product development of its now patent pending soluble fiber-based nutrition products in 2017. Glucose Health, Inc.'s flagship diabetic nutrition brand GlucoDown® is a dietary fiber-infused nutrition drink scientifically formulated to support balanced glucose levels particularly after meals. GlucoDown® competes in the diabetic nutrition category and is found on the shelves of national pharmacy chains alongside products such as Glucerna® (Abbott Laboratories, Abbott, ABT) and Boost® (Nestlé USA, Inc., Nestlé S.A., Nestlé, NSRGY). GlucoDown® offers health-conscious consumers a differentiated focus on providing dietary fiber's established metabolic benefits via a refreshing beverage offered in powdered drink flavors and iced teas. Glucose Health, Inc. also utilizes a variant of its patent pending formulation in its brand Fiber Up®, a delicious-tasting powdered beverage dietary fiber supplement targeting digestive and gut health. Scientifically formulated to compete with Metamucil® (The Procter & Gamble Company, P&G, PG), Fiber Up® builds upon the company's mission to make fiber supplementation effective and enjoyable. 'The federal government's recognition of dietary fiber as a nutrient of public health concern validates what has been our core mission since 2017' said Murray Fleming, CEO of Glucose Health, Inc. 'We anticipated this public health priority and began development work formulating GlucoDown® and Fiber Up® to give consumers effective but still flavorful ways to contribute to their overall metabolic health. We believe Glucose Health, Inc. is uniquely positioned at the intersection of evolving public health priorities and anticipated rising consumer demand.'Investor Contact: Investor Relations [email protected] OTC: GLUC

Associated Press
an hour ago
- Associated Press
CCHR wants electroshocking children prohibited under child abuse laws
LOS ANGELES, Calif., June 30, 2025 (SEND2PRESS NEWSWIRE) — Child and adolescent psychiatrists have issued a policy statement urging broader access to electroconvulsive therapy (ECT) for children and adolescents despite growing international condemnation of the practice on minors. Both the World Health Organization (WHO) and the United Nations Human Rights Office have called for an outright ban on ECT for children, explicitly stating: 'ECT is not recommended for children, and this should be prohibited through legislation.'[1] The Citizens Commission on Human Rights International (CCHR), a mental health industry watchdog, condemned the statement as 'medically reckless, legally dangerous, and morally indefensible.' CCHR is demanding federal and state lawmakers move urgently to outlaw the electroshocking of children, classifying it as a form of child abuse. ECT, also known as shock treatment, sends up to 460 volts of electricity through the brain to induce a grand mal seizure. This disruption of the brain's electrical activity alters its structure and function, an especially serious risk to the developing brains of children. Yet child psychiatrists not only call for expanded use of ECT on minors but also oppose 'any efforts—legal, legislative, and otherwise—to block access to ECT.' Through US Freedom of Information Act requests, CCHR uncovered that children as young as five have been electroshocked. The full scope remains hidden due to the lack of national transparency requirements on ECT usage. Internationally, some countries have already banned ECT entirely (e.g., Slovenia and Luxembourg). In the U.S., California prohibits it under age 12, and Texas under 16. In Western Australia, ECT on minors under 14 is illegal, with criminal penalties—including jail time—for administering it to children. CCHR was instrumental in helping secure that law, along with state bans in the US. Disturbingly, a child and adolescent psychiatry group has also called for more research involving ECT on youth, potentially exposing children under age 13 to an unproven and highly invasive procedure. The US Food and Drug Administration (FDA) restricts its use to individuals aged 13 and older for limited diagnoses. The psychiatry group's statement fails to disclose that brain damage is a known risk of ECT. Yet, the American Psychiatric Association concedes that 'ECT can result in persistent or permanent memory loss.' The joint WHO/UN report adds: 'People being offered ECT should also be made aware of all its risks and potential short- and long-term harmful effects, such as memory loss and brain damage.' [2] In June 2024, the California Supreme Court ruled that an ECT device manufacturer must warn doctors of the risks of brain damage and permanent memory loss.[3] In 2018, a US District Court judge found there was sufficient evidence for a jury to conclude that an ECT device could cause brain injury.[4] Neuropathologist Dr. Bennet Omalu—known for discovering chronic traumatic encephalopathy ( brain diseases or damage) in football players—publicly condemned ECT, stating: ' The amounts of electrical energy introduced to the human brain by ECT machines can be nothing but harmful and dangerous…. The patient who receives ECT therapy will manifest permanent and cumulative brain injury, which can be progressive over time and result in chronic encephalopathies and brain degeneration.' [5] Despite pediatric psychiatry's claim that ECT is 'safe and effective,' the FDA has never required manufacturers to prove ECT's safety or efficacy through clinical trials.[6] Internationally renowned researcher Prof. John Read reports that only 11 placebo-controlled trials of ECT have ever been conducted—all prior to 1985, and all deeply flawed. 'None found any benefit beyond the end of treatment,' he stated. Further, children's developing brains are 'particularly susceptible to the memory loss caused by ECT.' [7] Legal precedent exists for holding professionals and psychiatric facilities accountable for misleading parents about the safety and nature of treatment. In June 2024, an Arizona jury awarded $2.5 million in punitive damages to the family of a teen girl who suffered coercion and abuse at a troubled teen treatment facility. They successfully argued that they were misled by marketing materials portraying the program as therapeutic and safe, when it was abusive.[8] CCHR says that this same legal framework must apply to misleading promotion of ECT's benefits to desperate parents. Failing to disclose the full risks of ECT should be subject to the same scrutiny and liability as cases in the troubled teen treatment industry. CCHR asserts that electroshocking should not only be banned nationwide, but if administered to children, should be held accountable under child abuse laws. Jan Eastgate, president of CCHR International, stated, 'The electroshocking of children is without moral or scientific justification and should be indefensible under the law. As international bodies condemn it, and legal rulings establish precedent for holding programs accountable for misleading parents, the U.S. must act. We urge lawmakers at all levels to ban ECT, especially on minors, and define it as a form of child abuse.' CCHR, which was established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, recommends parents watch its documentary, Therapy or Torture: The Truth About Electroshock, with expert opinions about how ECT damages minds. To learn more, visit: Sources: [1] World Health Organization, OHCHR, 'Guidance on Mental Health, Human Rights and Legislation,' pp. 58 & 59 [2] [3] [4] 'ECT Litigation Update: Are Patients Being Warned of Brain Damage Risk?' MAD, 13 June 2019 [5] [6] [7] [8] MULTIMEDIA: Image link for media: Image caption: Through US Freedom of Information Act requests, CCHR uncovered that children as young as five have been electroshocked. The full scope remains hidden due to the lack of national transparency requirements on ECT usage. NEWS SOURCE: Citizens Commission on Human Rights Keywords: AP, ban ECT, child abuse laws, ECT usage, Citizens Commission on Human Rights, CCHR International, electroshock, Jan Eastgate, LOS ANGELES, Calif. This press release was issued on behalf of the news source (Citizens Commission on Human Rights) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127282 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.